DB:4CX

Stock Analysis Report

Executive Summary

Cyxone AB (publ), a clinical biotech company, develops immunomodulating drugs for the treatment of autoimmune diseases.

Risk Analysis

Earnings have declined by -55.92% per year over past 5 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK36K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Cyxone's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4CX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.3%

4CX

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

0.7%

4CX

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: 4CX underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 4CX underperformed the German Market which returned 15% over the past year.


Shareholder returns

4CXIndustryMarket
7 Day-7.3%1.0%2.0%
30 Day-19.8%-1.2%1.0%
90 Day-18.9%7.4%3.8%
1 Year0.7%0.7%7.1%6.8%18.6%15.1%
3 Yearn/a48.3%46.6%16.8%6.6%
5 Yearn/a11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is Cyxone's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cyxone undervalued compared to its fair value and its price relative to the market?

2.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4CX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4CX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4CX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 4CX is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4CX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4CX is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Cyxone forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

0.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4CX's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if 4CX's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4CX's revenue (0.2% per year) is forecast to grow slower than the German market (5% per year).

High Growth Revenue: 4CX's revenue (0.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 4CX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cyxone performed over the past 5 years?

-55.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4CX is currently unprofitable.

Growing Profit Margin: 4CX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4CX is unprofitable, and losses have increased over the past 5 years at a rate of -55.9% per year.

Accelerating Growth: Unable to compare 4CX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4CX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 4CX has a negative Return on Equity (-49.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cyxone's financial position?


Financial Position Analysis

Short Term Liabilities: 4CX's short term assets (SEK62.4M) exceed its short term liabilities (SEK3.4M).

Long Term Liabilities: 4CX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 4CX is debt free.

Reducing Debt: 4CX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 4CX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 4CX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4CX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 4CX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cyxone's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 4CX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 4CX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4CX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4CX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4CX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ola Skanung 0

0.3yrs

Tenure

0

Mr. Ola Skanung serves as the Chief Financial Officer of Aptahem AB (publ) since April 20, 2016. Mr. Skanung serves as the Chief Financial Officer of Cyxone AB (publ) and serves as its Interim Chief Execut ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56.6%.


Top Shareholders

Company Information

Cyxone AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cyxone AB (publ)
  • Ticker: 4CX
  • Exchange: DB
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr177.916m
  • Listing Market Cap: kr16.937m
  • Shares outstanding: 49.08m
  • Website: https://www.cyxone.com

Number of Employees


Location

  • Cyxone AB (publ)
  • Adelgatan 21
  • Malmö
  • Skåne County
  • 221 22
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYXOOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2016
4CXDB (Deutsche Boerse AG)YesShare CapitalDEEURJun 2016

Biography

Cyxone AB (publ), a clinical biotech company, develops immunomodulating drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical phase II program for rheumatoid arthritis and T20K that would enter clinical phase I for multiple sclerosis. The company was founded in 2015 and is based in Malmö, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 22:50
End of Day Share Price2020/02/17 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.